AU2007297754B2 - Heterocyclic inhibitors of c-MET and uses thereof - Google Patents

Heterocyclic inhibitors of c-MET and uses thereof Download PDF

Info

Publication number
AU2007297754B2
AU2007297754B2 AU2007297754A AU2007297754A AU2007297754B2 AU 2007297754 B2 AU2007297754 B2 AU 2007297754B2 AU 2007297754 A AU2007297754 A AU 2007297754A AU 2007297754 A AU2007297754 A AU 2007297754A AU 2007297754 B2 AU2007297754 B2 AU 2007297754B2
Authority
AU
Australia
Prior art keywords
aliphatic
optionally substituted
ring
pct
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2007297754A
Other languages
English (en)
Other versions
AU2007297754A1 (en
Inventor
Alexander Aronov
Jon Come
John Court
David Deininger
David Lauffer
Pan Li
Kira Mcginty
Suganthini Nanthakumar
Dean Stamos
Kirk Tanner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertex Pharmaceuticals Inc
Original Assignee
Vertex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc
Publication of AU2007297754A1 publication Critical patent/AU2007297754A1/en
Application granted granted Critical
Publication of AU2007297754B2 publication Critical patent/AU2007297754B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D497/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D497/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D497/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AU2007297754A 2006-09-18 2007-09-18 Heterocyclic inhibitors of c-MET and uses thereof Ceased AU2007297754B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US84535606P 2006-09-18 2006-09-18
US60/845,356 2006-09-18
PCT/US2007/020222 WO2008036272A1 (en) 2006-09-18 2007-09-18 HETEROCYCLIC INHIBITORS OF c-MET AND USES THEREOF

Publications (2)

Publication Number Publication Date
AU2007297754A1 AU2007297754A1 (en) 2008-03-27
AU2007297754B2 true AU2007297754B2 (en) 2012-05-17

Family

ID=39092942

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007297754A Ceased AU2007297754B2 (en) 2006-09-18 2007-09-18 Heterocyclic inhibitors of c-MET and uses thereof

Country Status (9)

Country Link
US (1) US8481538B2 (en:Method)
EP (1) EP2066676A1 (en:Method)
JP (1) JP2010519174A (en:Method)
CN (1) CN101796056A (en:Method)
AU (1) AU2007297754B2 (en:Method)
CA (1) CA2663528A1 (en:Method)
MX (1) MX2009002842A (en:Method)
NZ (1) NZ575548A (en:Method)
WO (1) WO2008036272A1 (en:Method)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2009001250A1 (es) * 2008-05-21 2010-02-05 Sal del acido dihidroclorico y dibencensulfonico de 2-fluoro-n-metil-4-[7-(quinolin-6-ilmetil)imidazol[1,2-b][1,2,4]1,2,4]triazin-2-il]benzamida; compuestos intermediarios; procesos de preparacion; composicion farmaceutica; y uso para tratar cancer, aterosclerosis, fibrosis pulmonar, enfermedad renal, entre otras.
WO2010141275A1 (en) * 2009-06-01 2010-12-09 Merck Sharp & Dohme Corp. Pyrazine carboxamide orexin receptor antagonists
CU24167B1 (es) 2009-12-31 2016-03-31 Hutchison Medipharma Ltd Derivados de triazolopirazinas sustituidas como inhibidores del receptor c-met o hgf para tratar el cáncer
EA025281B9 (ru) 2010-05-17 2017-08-31 Инкозен Терапьютикс Пвт. Лтд. СОЕДИНЕНИЯ 3,5-ДИЗАМЕЩЕННОГО-3H-ИМИДАЗО[4,5-b]ПИРИДИНА И 3,5-ДИЗАМЕЩЕННОГО-3H-[1,2,3]ТРИАЗОЛО[4,5-b]ПИРИДИНА КАК МОДУЛЯТОРЫ ПРОТЕИНКИНАЗ
CN104321322A (zh) 2012-03-30 2015-01-28 理森制药股份公司 作为c-met蛋白激酶调节剂的新型3,5-二取代-3h-咪唑并[4,5-b]吡啶和3,5-二取代-3h-[1,2,3]三唑并[4,5-b]吡啶化合物
TW201613919A (en) * 2014-07-02 2016-04-16 Pharmacyclics Llc Inhibitors of Bruton's tyrosine kinase
EP3319968A1 (en) 2015-07-06 2018-05-16 Rodin Therapeutics, Inc. Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase
WO2017007756A1 (en) 2015-07-06 2017-01-12 Rodin Therapeutics, Inc Hetero-halo inhibitors of histone deacetylase
WO2018132531A1 (en) 2017-01-11 2018-07-19 Rodin Therapeutics, Inc. Bicyclic inhibitors of histone deacetylase
CA3071861A1 (en) 2017-08-07 2019-02-14 Rodin Therapeutics, Inc. Bicyclic inhibitors of histone deacetylase
WO2020118683A1 (en) * 2018-12-14 2020-06-18 Lynk Pharmaceuticals Co. Ltd. Benzamides of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof
TR202010296A1 (tr) * 2020-06-30 2022-01-21 Anadolu Ueniversitesi Akt inhibisyonu aracılığıyla a549 hücrelerinde sitotoksik ve apoptotik etki gösteren yeni triazol ve triazolotiyadiazin türevleri

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007064797A2 (en) * 2005-11-30 2007-06-07 Vertex Pharmaceuticals Incorporated Inhibitors of c-met and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60112272T2 (de) * 2000-04-27 2006-05-24 Astellas Pharma Inc. Imidazopyridin-derivate
RU2005122484A (ru) * 2002-12-18 2006-01-20 Вертекс Фармасьютикалз Инкорпорейтед (Us) Композиции, используемые в качестве ингибиторов протеинкиназ
US7122548B2 (en) * 2003-07-02 2006-10-17 Sugen, Inc. Triazolotriazine compounds and uses thereof
US7732468B2 (en) * 2006-11-15 2010-06-08 Cytovia, Inc. 3-aryl-6-aryl-[ 1,2,4]triazolo[3,4-b][1,3,4]thiadiazoles and related compounds as activators of caspases and inducers of apoptosis and the use thereof
EA201000051A1 (ru) * 2007-07-13 2010-08-30 ГЛАКСОСМИТКЛАЙН ЭлЭлСи Противовирусные соединения, композиции и способы использования
MY152040A (en) * 2008-02-05 2014-08-15 Sanofi Aventis Triazolopyridazines as par1 inhibitors, production thereof, and use as medicaments
AU2010226490A1 (en) * 2009-03-20 2011-10-06 Amgen Inc. Inhibitors of PI3 kinase

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007064797A2 (en) * 2005-11-30 2007-06-07 Vertex Pharmaceuticals Incorporated Inhibitors of c-met and uses thereof

Also Published As

Publication number Publication date
NZ575548A (en) 2011-09-30
US8481538B2 (en) 2013-07-09
WO2008036272A1 (en) 2008-03-27
US20100144739A1 (en) 2010-06-10
CA2663528A1 (en) 2008-03-27
MX2009002842A (es) 2009-05-27
JP2010519174A (ja) 2010-06-03
EP2066676A1 (en) 2009-06-10
CN101796056A (zh) 2010-08-04
AU2007297754A1 (en) 2008-03-27

Similar Documents

Publication Publication Date Title
AU2007297754B2 (en) Heterocyclic inhibitors of c-MET and uses thereof
AU2006320580B2 (en) Inhibitors of c-Met and uses thereof
US8937064B2 (en) Pyrazolo[1,5-a]pyrimidines useful as JAK2 inhibitors
NZ575346A (en) 5- (2-furyl)-1, 3-thiazole derivatives useful as inhibitors of phosphatidylinositol 3-kinase
WO2007117494A1 (en) Deazapurines useful as inhibitors of janus kinases
AU2009281822A1 (en) cMET inhibitors
AU2010250055A1 (en) Tri-cyclic pyrazolopyridine kinase inhibitors
KR20110039278A (ko) 단백질 키나제 억제제
EP2032562A2 (en) Selective inhibitors of rock protein kinase and uses thereof
CA2681516A1 (en) Compounds useful as inhibitors of janus kinases
AU2010258903A1 (en) Inhibitors of phosphatidylinositol 3-kinase
US20110135603A1 (en) Inhibitors of phosphatidylinositol 3-kinase
AU2010216219A1 (en) Tetrahydrothiazolopyridine inhibitors of phosphatidylinositol 3-kinase
HK1146825A (en) Heterocyclic inhibitors of c-met and uses thereof
HK1161230A (en) Protein kinase inhibitors

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired